months. Patients were considered to be cured when stimulated Ct was undetectable. Age, gender, tumour size, neck lymph-node metastasis, TNM stage, extent of surgical resection, postoperative external-beam radiation, and postoperative chemotherapy were analysed in all patients.

Findings: Of 132 MTC patients who had locally curative surgery, 68 (51.5%) had a tumour larger than 4 cm. 92 patients (69.7%) were biochemically cured and 76 (57.6%) cases involved lymph-node metastasis. Biochemical cure was significantly correlated with extrathyroid extension ($p < 0.005$), tumour size ($p < 0.005$), and lymph-node metastases ($p < 0.0001$). The 5-year and 10-year cancer-specific cumulative survival rates were 73.4% and 19.6%, respectively. In univariate analysis, age and the presence of node metastases were significant prognostic factors. Only age remained an independent prognostic factor in multivariate analysis.

Interpretation: Clinical outcome is significantly better for MTC patients younger than 45 years, regardless of tumour size and node metastases. The younger age at diagnosis and modified radical neck dissection might enhance the outcome. Age was a unique independent prognostic factor. Patients with MTC should be regarded as having systemic disease; and patients with a tumour larger than 4.0 cm, bilateral neck node metastases, and accompanying systemic symptoms are unlikely to be biochemically cured, even with extensive surgery.

Funding: None.

The authors declared no conflicts of interest.

**P18 ECONOMIC EVALUATION OF ADJUVANT TRASTUZUMAB IN THE TREATMENT OF EARLY, HER2/NEU-OVEREXPRESSING BREAST CANCER IN SINGAPORE**

G. De Lima Lopes. Johns Hopkins Singapore International Medical Centre, Republic of Singapore. Johns Hopkins University School of Medicine, Baltimore, MD, USA

**Background:** Trastuzumab has revolutionised the way we treat early, HER2/neu-positive breast cancer, because it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in the adjuvant setting in Asia. This study aimed to be the first economic evaluation of trastuzumab in Singapore and Asia, assessing its net economic gains to society.

**Methods:** An analytic model was used to estimate societal costs (and benefits) of treatment with trastuzumab in Singapore. Direct costs were derived from actual patient costs at four treatment centres in Singapore – two private and two public centres, comprising 60–70% of all patients with cancer. Indirect costs were assessed as the loss of productivity caused by the disease or treatment. Benefits to society were based on extra years of productivity (measured by GNI per capita) resulting from the quality-adjusted life-years (QALY) saved with the use of trastuzumab, as determined in the models by Kurian (J Clin Oncol 2007), Liberato (J Clin Oncol 2007), and Garrison (Cancer 2007). Sensitivity analysis was performed.

**Findings:** Incremental costs in Singapore were $26,971.05 (all costs are in 2005 US dollars). The average cost per QALY was $19,174.59 (median $18,993.70). Costs (benefits) to society ranged from a cost of $79.42 to a benefit of $9,263.06 per person, depending on the model used (average benefit $4,375.89, median $3,944.03). Sensitivity analysis ranged from a cost of $10,685.00 to a benefit of $17,298.79.

**Interpretation:** Treatment with adjuvant trastuzumab is likely to generate net societal economic benefits in Singapore. Nevertheless, the lower range of possible outcomes does not refute the possibility that treatment may actually generate costs; however, these costs fall within the range of acceptable cost-effectiveness.

**Funding:** Johns Hopkins Singapore.

The authors declared no conflicts of interest.

doi:10.1016/j.ejcsup.2011.02.019

**P19 HEPATITIS C VIRAL INFECTION AND OTHER RISK FACTORS FOR B-CELL NON-HODGKINS LYMPHOMA IN ADULT EGYPTIANS – WITHDRAWN**

**P20 NATIONAL LIVER TISSUE BANK AND CLINICAL DATABASE IN CHINA**

Y. Yang, Y. Liu, M. Wei, Y. Wu, J. Gao, L. Liu, W. Zhou *, H. Wang *, M. Wu. Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

**Background:** To develop standardised and well-rounded material for hepatology research.

**Methods:** The National Liver Tissue Bank (NLTB) project began in China in 2008, to make well-characterised and optimally preserved liver tumour tissue available and to create a clinical database.

**Findings:** From December, 2008, to June, 2010, more than 3000 individuals enrolled at the NLTB as liver tumour donors, including 2317 cases of newly diagnosed hepatocellular carcinoma (HCC), and about 1000 cases diagnosed as benign or malignant liver tumours. The clinical database and sample store can be managed easily and correctly with the data management platform used.

**Interpretation:** We believe that the high-quality samples and database with detailed information will become the cornerstone of hepatology research, particularly in studies of diagnosis and new treatments for HCC and other liver disease.

**Funding:** The National Liver Tissue Bank project in China was supported by the Chinese Key Project for Infectious Diseases.

The authors declared no conflicts of interest.

doi:10.1016/j.ejcsup.2011.02.021